Comparison of warfarin, low-molecular-weight dextran, aspirin, and subcutaneous heparin in prevention of venous thromboembolism following total hip replacement.
D001241:Aspirin / Q000009:adverse effects / Q000627:therapeutic use*; D003911:Dextrans / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced; D006493:Heparin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006621:Hip Joint / Q000601:surgery; D006801:Humans; D007279:Injections, Subcutaneous; D007595:Joint Prosthesis; D008297:Male; D008875:Middle Aged; D008970:Molecular Weight; D011183:Postoperative Complications / Q000517:prevention & control*; D011446:Prospective Studies; D011655:Pulmonary Embolism / Q000517:prevention & control; D011859:Radiography; D013923:Thromboembolism / Q000000981:diagnostic imaging / Q000209:etiology / Q000517:prevention & control*; D013924:Thrombophlebitis / Q000000981:diagnostic imaging / Q000209:etiology / Q000517:prevention & control; D014859:Warfarin / Q000009:adverse effects / Q000627:therapeutic use
D003911:Dextrans; D014859:Warfarin; D006493:Heparin; D001241:Aspirin